SK16022002A3 - Inhibítory aromatázy a monoklonálne anti-HER2 protilátky ako antitumorové činidlá - Google Patents

Inhibítory aromatázy a monoklonálne anti-HER2 protilátky ako antitumorové činidlá Download PDF

Info

Publication number
SK16022002A3
SK16022002A3 SK1602-2002A SK16022002A SK16022002A3 SK 16022002 A3 SK16022002 A3 SK 16022002A3 SK 16022002 A SK16022002 A SK 16022002A SK 16022002 A3 SK16022002 A3 SK 16022002A3
Authority
SK
Slovakia
Prior art keywords
her2
aromatase inhibitor
hormone
achieve
superadditive
Prior art date
Application number
SK1602-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Giorgio Massimini
Gabriella Piscitelli
Dinesh Purandare
Original Assignee
Pharmacia Italia S. P. A.
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia S. P. A., Pharmacia & Upjohn Company filed Critical Pharmacia Italia S. P. A.
Publication of SK16022002A3 publication Critical patent/SK16022002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1602-2002A 2000-05-15 2001-04-19 Inhibítory aromatázy a monoklonálne anti-HER2 protilátky ako antitumorové činidlá SK16022002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
PCT/EP2001/004468 WO2001087334A1 (fr) 2000-05-15 2001-04-19 Inhibiteurs des aromatases et anticorps monoclonaux anti-her2 utiles en tant qu'agents antitumoraux

Publications (1)

Publication Number Publication Date
SK16022002A3 true SK16022002A3 (sk) 2003-04-01

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1602-2002A SK16022002A3 (sk) 2000-05-15 2001-04-19 Inhibítory aromatázy a monoklonálne anti-HER2 protilátky ako antitumorové činidlá

Country Status (20)

Country Link
EP (1) EP1282440A1 (fr)
JP (1) JP2003533490A (fr)
KR (1) KR20030014223A (fr)
CN (1) CN1429118A (fr)
AU (1) AU784617B2 (fr)
BR (1) BR0110732A (fr)
CA (1) CA2409652A1 (fr)
CZ (1) CZ20023748A3 (fr)
EA (1) EA005931B1 (fr)
EE (1) EE200200622A (fr)
HK (1) HK1054200A1 (fr)
HU (1) HUP0301877A2 (fr)
IL (1) IL152389A0 (fr)
MX (1) MXPA02011194A (fr)
NO (1) NO20025302D0 (fr)
NZ (1) NZ523004A (fr)
PL (1) PL360153A1 (fr)
SK (1) SK16022002A3 (fr)
WO (1) WO2001087334A1 (fr)
ZA (1) ZA200209815B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
PL217410B1 (pl) 2000-05-19 2014-07-31 Genentech Inc Zastosowanie antagonisty ErbB, antagonista ErbB do zastosowania w metodzie leczenia raka i sposób identyfikacji pacjenta skłonnego do korzystnej odpowiedzi na antagonistę ErbB przy leczeniu raka
EP1377298B1 (fr) * 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane pour traiter les troubles hormonodependants
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
US7919098B2 (en) 2002-03-26 2011-04-05 Zensun ( Shanghai ) Sci & Tech Co., Ltd. ErbB-3 based methods and compositions for treating neoplasms
KR20050059001A (ko) * 2002-07-01 2005-06-17 사비언트 파마슈티컬즈 인코퍼레이티드 치료적 처리를 위한 조성물 및 방법
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
KR20080019733A (ko) * 2004-07-16 2008-03-04 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
SI1850874T1 (sl) 2005-02-23 2014-01-31 Genentech, Inc. Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba
WO2007045027A1 (fr) 2005-10-19 2007-04-26 Chavah Pty Ltd Réduction des effets secondaires des inhibiteurs de l'aromatase employés dans le traitement du cancer du sein
AU2008223069B2 (en) 2007-03-02 2012-12-13 F. Hoffmann-La Roche Ag Predicting response to a HER dimerisation inhibitor based on low HER3 expression
EP2171090B1 (fr) 2007-06-08 2013-04-03 Genentech, Inc. Marqueurs d'expression de gène de résistance tumorale à un traitement par inhibiteur her2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
WO2010136569A1 (fr) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulateurs de la signalisation her2 chez des patients exprimant her2 souffrant d'un cancer de l'estomac
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
EP2643353A1 (fr) 2010-11-24 2013-10-02 Novartis AG Molécules multi-spécifiques
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CN102068429B (zh) * 2010-12-28 2011-12-14 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
SG11201402510TA (en) 2011-11-30 2014-06-27 Genentech Inc Erbb3 mutations in cancer
WO2013083810A1 (fr) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification de non-répondeurs aux inhibiteurs de her2
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
WO2014015137A2 (fr) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions et méthodes de traitement de maladies dysprolifératives
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
CN107405353B (zh) 2014-10-22 2021-07-30 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
WO2017066827A1 (fr) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Procédés de réduction de la densité mammaire à la mammographie et/ou du risque de cancer du sein
EP3454863A1 (fr) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Polythérapies pour le traitement du cancer
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
AU2020287392A1 (en) 2019-06-03 2021-12-23 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Also Published As

Publication number Publication date
EE200200622A (et) 2004-06-15
IL152389A0 (en) 2003-05-29
AU5630901A (en) 2001-11-26
JP2003533490A (ja) 2003-11-11
CZ20023748A3 (cs) 2003-04-16
NZ523004A (en) 2004-09-24
CN1429118A (zh) 2003-07-09
HK1054200A1 (zh) 2003-11-21
AU784617B2 (en) 2006-05-18
BR0110732A (pt) 2003-02-04
PL360153A1 (en) 2004-09-06
NO20025302L (no) 2002-11-05
EP1282440A1 (fr) 2003-02-12
EA005931B1 (ru) 2005-08-25
ZA200209815B (en) 2003-12-03
EA200201213A1 (ru) 2003-04-24
HUP0301877A2 (hu) 2003-09-29
WO2001087334A1 (fr) 2001-11-22
NO20025302D0 (no) 2002-11-05
KR20030014223A (ko) 2003-02-15
MXPA02011194A (es) 2003-03-10
CA2409652A1 (fr) 2001-11-22

Similar Documents

Publication Publication Date Title
SK16022002A3 (sk) Inhibítory aromatázy a monoklonálne anti-HER2 protilátky ako antitumorové činidlá
US20050032759A1 (en) Antitumor combined therapy
AU2012229147B2 (en) Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
JP5220315B2 (ja) 抗ＥｐＣＡＭ免疫グロブリン
JP2005533001A5 (fr)
JP2023085422A (ja) 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
CN113018429A (zh) 治疗卵巢癌的药物组合
JP7352582B2 (ja) Ｓｕｍｏ活性化酵素阻害剤及び抗ｃｄ２０抗体の投与
JP2023502585A (ja) 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害
WO2017205216A1 (fr) Association de pembrolizumab et d'abémaciclib pour le traitement du cancer
KR20190110063A (ko) 항-vegfr-2 항체
US20230398229A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
WO2023160517A1 (fr) Composition pharmaceutique comprenant des anticorps mixtes anti-ctla4 et anti-pd1 et son utilisation thérapeutique
WO2024158840A2 (fr) Méthodes et compositions pour polythérapie
WO2021088853A1 (fr) Association de médicaments d'un dérivé de quinoléine et d'un anticorps monoclonal pd -1
EA047600B1 (ru) КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
NZ614427B2 (en) Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers

Legal Events

Date Code Title Description
FC9A Refused patent application